RxDoctor Payments Data

Christina Enzmann, MD

Obstetrics & Gynecology · Baltimore, MDNPI 1780727420

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $51,975 of the $62,883 with a category attached, or 82.7%. AbbVie accounts for 99.6% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $61,372 and has fallen 100.0% since, to $13 in 2024. Among obstetrics & gynecology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$62,883in general payments, 2019–2025

Across 104 payments — averaging $604.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$63K
  • AMAG Pharmaceuticals, Inc.$75
  • Bayer$40
  • Millicent US Inc$38
  • Mylan Pharmaceuticals Inc.$26
  • Axonics, Inc.$22
  • plus $53 from 3 others

What the payments were for

  • Speaking & faculty fees$51,97583%
  • Travel & lodging$9,36015%
  • Food & beverage$1,4162%
  • Education$1320%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,883 in reported general payments places this provider in the 95th percentile of 842 obstetrics & gynecology providers in Maryland.

See all obstetrics & gynecology providers in Maryland

Medicare billing

Part B allowed, 2024
$27,219
Medicare patients
117
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol101$9,596
IntrarosaPrasterone (Dhea)14$9,456
YuvafemEstradiol39$7,812
GemtesaVibegron11$7,145
EstringEstradiol11$5,622
OsphenaOspemifene15$5,358
PremarinEstrogens, Conjugated12$4,776
ValacyclovirValacyclovir Hcl38$3,006
Estradiol (Twice Weekly)Estradiol53$2,175
Estradiol (Once Weekly)Estradiol15$2,001
ProgesteroneProgesterone, Micronized22$704
Triamcinolone Acetonide15$519
DottiEstradiol12$431
Oxybutynin Chloride ErOxybutynin Chloride28$403
Terconazole14$379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AMAG Pharmaceuticals, Inc.Intrarosa$75$9,45614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 842 obstetrics & gynecology providers in Maryland.

Other obstetrics & gynecology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →